Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oligometastatic sarcoma treated with Curative intent Ablative Radiotherapy (OSCAR): A multicenter study on behalf of AIRO (Italian association of Radiotherapy and clinical Oncology).
Franceschini D, Greto D, Dicuonzo S, Navarria F, Federico M, La Vecchia M, Sangalli C, Allajbej A, Di Cristina L, Mazzola R, Pontoriero A, Montesi G, Navarria P, Baldaccini D, Clerici E, Lo Faro L, Franzese C, Di Biase S, Pergolizzi S, Alongi F, Bignardi M, Fazio I, Mascarin M, Jereczek-Fossa BA, Livi L, Scorsetti M. Franceschini D, et al. Among authors: baldaccini d. Radiother Oncol. 2024 Feb;191:110078. doi: 10.1016/j.radonc.2023.110078. Epub 2023 Dec 30. Radiother Oncol. 2024. PMID: 38163485
Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.
D'Agostino GR, Badalamenti M, Stefanini S, Baldaccini D, Franzese C, Faro LL, Di Cristina L, Vernier V, Reggiori G, Scorsetti M. D'Agostino GR, et al. Among authors: baldaccini d. Prostate. 2024 Mar;84(4):368-375. doi: 10.1002/pros.24657. Epub 2023 Dec 19. Prostate. 2024. PMID: 38112222 Clinical Trial.
Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: The POPART multicentric prospective study.
Ferrario F, Franzese C, Faccenda V, Vukcaj S, Belmonte M, Lucchini R, Baldaccini D, Badalamenti M, Andreoli S, Panizza D, Magli A, Scorsetti M, Arcangeli S. Ferrario F, et al. Among authors: baldaccini d. Clin Transl Radiat Oncol. 2023 Nov 25;44:100704. doi: 10.1016/j.ctro.2023.100704. eCollection 2024 Jan. Clin Transl Radiat Oncol. 2023. PMID: 38111610 Free PMC article.
Oligometastatic Prostate Cancer Treated with Stereotactic Body Radiation Therapy: The Role of Three-Dimensional Tumour Volume in Patient Survival.
Franzese C, Lucchini R, Roghi M, Badalamenti M, Baldaccini D, Comito T, Franceschini D, Navarria P, Di Cristina L, Lo Faro L, Galdieri C, Reggiori G, Mancosu P, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: baldaccini d. Clin Oncol (R Coll Radiol). 2023 Dec;35(12):e649-e656. doi: 10.1016/j.clon.2023.09.004. Epub 2023 Sep 16. Clin Oncol (R Coll Radiol). 2023. PMID: 37775459
PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
Francolini G, Banini M, Di Cataldo V, Detti B, Caini S, Loi M, Simontacchi G, Desideri I, Greto D, Valzano M, Roghi M, Serni S, Vaggelli L, Salvestrini V, Visani L, Becherini C, Olmetto E, Franzese C, Baldaccini D, Scorsetti M, Sollini M, Chiti A, Meattini I, Valicenti RK, Livi L. Francolini G, et al. Among authors: baldaccini d. Prostate. 2023 Sep;83(12):1201-1206. doi: 10.1002/pros.24579. Epub 2023 Jun 8. Prostate. 2023. PMID: 37290915
Early biochemical outcomes following PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results.
Francolini G, Ganovelli M, Di Cataldo V, Detti B, Caini S, Loi M, Simontacchi G, Desideri I, Greto D, Valzano M, Serni S, Vaggelli L, Salvestrini V, Visani L, Becherini C, Olmetto E, Franzese C, Baldaccini D, Scorsetti M, Sollini M, Chiti A, Meattini I, Valicenti RK, Livi L. Francolini G, et al. Among authors: baldaccini d. Clin Exp Metastasis. 2023 Apr;40(2):197-201. doi: 10.1007/s10585-023-10204-y. Epub 2023 Apr 3. Clin Exp Metastasis. 2023. PMID: 37012498 Free PMC article.
The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C, Marini B, Baldaccini D, Badalamenti M, Navarria P, Bellu L, Franceschini D, Comito T, Clerici E, Teriaca MA, Massaro M, Di Cristina L, Lo Faro L, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: baldaccini d. J Cancer Res Clin Oncol. 2023 Jul;149(8):4411-4417. doi: 10.1007/s00432-022-04352-z. Epub 2022 Sep 15. J Cancer Res Clin Oncol. 2023. PMID: 36109401
Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study.
Navarria P, Baldaccini D, Clerici E, Marini B, Cozzi L, Franceschini D, Bertuzzi AF, Quagliuolo V, Torri V, Colombo P, Franzese C, Bellu L, Scorsetti M. Navarria P, et al. Among authors: baldaccini d. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):762-770. doi: 10.1016/j.ijrobp.2022.08.028. Epub 2022 Aug 18. Int J Radiat Oncol Biol Phys. 2022. PMID: 35987453 Clinical Trial.
Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy.
Massaro M, Franceschini D, Spoto R, Dominici L, Franzese C, Baldaccini D, Marini B, di Cristina L, Marzo MA, Lo Faro L, Paganini L, Reggiori G, Galdieri C, Testori A, Scorsetti M. Massaro M, et al. Among authors: baldaccini d. Curr Oncol. 2022 Jul 12;29(7):4893-4901. doi: 10.3390/curroncol29070388. Curr Oncol. 2022. PMID: 35877248 Free PMC article.
24 results